Skip to search boxSkip to navigationSkip to main content

Insomnia severity is an indicator of suicidal ideation during a depression clinical trial

  • William Vaughn McCall(corresponding author)
    ,
  • Jill N. Blocker
    ,
  • Ralph D'Agostino
    ,
  • James Kimball
    ,
  • Niki Boggs
    ,
  • Barbara Lasater
*Corresponding author for this work
  • Wake Forest University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objective: Insomnia has been linked to suicidal ideas and suicide death in cross-sectional and longitudinal population-based studies. A link between insomnia and suicide has not been previously examined in the setting of a clinical trial. Herein we describe the relationship between insomnia and suicidal thinking during the course of a clinical trial for depression with insomnia. Methods: Sixty patients aged 41.5 ± 12.5 years (2/3 women) with major depressive episode and symptoms of insomnia received open-label fluoxetine for 9 weeks and also received blinded, randomized eszopiclone 3 mg or placebo at bedtime after the first week of fluoxetine. Insomnia symptoms were assessed with the Insomnia Severity Index (ISI), and suicidal ideation was assessed with The Scale for Suicide Ideation (SSI). Depression symptoms were assessed with the depressed mood item and the anhedonia item from the Hamilton Rating Scale for Depression-24 (HRSD24), as well as a sum score for all non-sleep and non-suicide items from the HRSD (HRSD20). Measurements were taken at baseline and weeks 1, 2, 4, 6, and 8. SSI was examined by generalized linear mixed models for repeated measures as the outcome of interest for all 60 participants with ISI and various mood symptoms as independent variables, with adjustment for age, gender, treatment assignment, and baseline SSI. Results: Higher levels of insomnia corresponded to significantly greater intensity of suicidal thinking (p< 0.01). The depressed mood item of the HRSD, and the sum of the HRSD20, both corresponded to greater suicidal thinking (p< 0.001). The anhedonia item did not correspond with suicidal thinking. When both ISI and the depressed mood item, or ISI and the anhedonia item, were included together in the same model, the ISI remained an independent predictor of suicidal thinking. Conclusions: The results support the concept that insomnia may be a useful indicator for suicidal ideation and now extend this idea into clinical trials. Insomnia remains an independent indicator of suicidal ideation, even taking into account the core symptoms of depression such as depressed mood and anhedonia. The complaint of insomnia during a depression clinical trial might indicate that more direct questioning about suicide is warranted.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 822-827 (6 pages)

Journal (Volume, Issue Number)

Sleep Medicine (Volume 11, Issue 9)

Publication milestones

  • Published - 10/2010

Publication status

Published - 10/2010

ISSN

1389-9457

Publication IDs

  • Scopus: 84755161818
  • PubMed: 20478741
  • ORCID: /0000-0001-5035-7858/work/58927685
  • ORCID: /0000-0001-9919-3380/work/58927851

Publication metrics

Metrics

Scopus
citations
Fractional count
2
Fractional count
0.29
Fractional count
5
Fractional count
0.71
Fractional count
2
Fractional count
1
SciVal
FWCI
9.93
SciVal
Author count
7
SciVal
citations
131
SciVal
Paper percentile
97
SciVal
Top percentile
5

PlumX, opens in new tab

Captures
231
Citation count
202
Social media
14
Mentions
1

Funding Details

This work was supported by NIMH, NIH, Sepracor, and Mini Mitter. Vaughn McCall has received support and been a speaker and consultant for Sepracor, is a consultant for Sealy, Inc, and has had research supported by Sanofi, Corcept, and Somaxon. James Kimball is a speaker for Pfizer and Astra Zeneca. NIH MH70821 and M01-RR07122, as well as funding and medications from Sepracor, and funding and material support from Mini Mitter ClinicalTrials.gov Identifier: NCT00247624.
FundersFunding numbers
NIH
-
NIMH
R34MH070821
Sepracor Inc.
NCT00247624